Merrimack commences MM-121 Study in cancer patients
MM-121 is a fully human monoclonal antibody that targets ErbB3. The study is intended to assess the safety and pharmacokinetics of MM-121 when administered in combination with cetuximab
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.